{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:23:23Z","timestamp":1761128603804,"version":"3.33.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.jbspin.2007.04.009","type":"journal-article","created":{"date-parts":[[2007,8,10]],"date-time":"2007-08-10T18:08:55Z","timestamp":1186769335000},"page":"606-611","source":"Crossref","is-referenced-by-count":7,"title":["Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"74","author":[{"given":"Anne Grimstvedt","family":"Kvalvik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liv","family":"Lefsaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri","family":"Dyvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan Gorgas","family":"Brun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.jbspin.2007.04.009_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/ard.2005.044941","article-title":"Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF-alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases","volume":"64","author":"Furst","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2007.04.009_bib2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/ard.2005.039339","article-title":"Great expectations of modern RA treatment","volume":"64","author":"Irvine","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2007.04.009_bib3","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alfa monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2007.04.009_bib4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2007.04.009_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2007.04.009_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"Quinn","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2007.04.009_bib7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","article-title":"Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2007.04.009_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2007.04.009_bib9","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2007.04.009_bib10","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1002\/art.22193","article-title":"Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials","volume":"54","author":"Zink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2007.04.009_bib11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/rheumatology\/41.6.601","article-title":"The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice?","volume":"41","author":"Fransen","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2007.04.009_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1070-3241(16)30059-1","article-title":"Linking outcomes measurement to continual improvement: the serial \u201cV\u201d way of thinking about improving clinical care","volume":"20","author":"Batalden","year":"1994","journal-title":"Jt Comm J Qual Improv"},{"key":"10.1016\/j.jbspin.2007.04.009_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/keh364","article-title":"The NICE reappraisal of biologics in 2005: what rheumatologists need to know","volume":"44","author":"Bansback","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2007.04.009_bib14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/ard.2004.023473","article-title":"Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept","volume":"64","author":"Feltelius","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2007.04.009_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.62.5.419","article-title":"Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis","volume":"62","author":"Vrijhoef","year":"2003","journal-title":"Ann Rheum Dis"},{"year":"2000","series-title":"The EULAR handbook of clinical assessments in rheumatoid arthritis. Nijmegen, Alpen aan den Rijn","author":"Van Riel","key":"10.1016\/j.jbspin.2007.04.009_bib16"},{"key":"10.1016\/j.jbspin.2007.04.009_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2007.04.009_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"year":"1988","series-title":"Applied regression analysis and other multivariable methods","author":"Kleinbaum","key":"10.1016\/j.jbspin.2007.04.009_bib19"},{"year":"1995","series-title":"Survival analysis. A practical approach","author":"Parmar","key":"10.1016\/j.jbspin.2007.04.009_bib20"},{"year":"1995","series-title":"An introduction to categorical data analysis","author":"Agresti","key":"10.1016\/j.jbspin.2007.04.009_bib21"},{"key":"10.1016\/j.jbspin.2007.04.009_bib22","first-page":"S188","article-title":"A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases","volume":"23","author":"Kvien","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2007.04.009_bib23","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2007.04.009_bib24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2007.04.009_bib25","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2007.04.009_bib26","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/ard.2006.062497","article-title":"Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis","volume":"66","author":"Jacobsson","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2007.04.009_bib27","first-page":"1664","article-title":"Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis","volume":"125","author":"Wallenius","year":"2005","journal-title":"Tidsskr Nor Laegeforen"},{"key":"10.1016\/j.jbspin.2007.04.009_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jbspin.2004.08.008","article-title":"Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice","volume":"72","author":"Wendling","year":"2005","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2007.04.009_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jbspin.2005.07.002","article-title":"Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community","volume":"73","author":"Genta","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2007.04.009_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jbspin.2006.03.008","article-title":"Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network","volume":"74","author":"Ducoulombier","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2007.04.009_bib31","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2007.04.009_bib32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2007.04.009_bib33","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","article-title":"Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France","volume":"73","author":"Saint Marcoux","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2007.04.009_bib34","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/art.21582","article-title":"Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center","volume":"53","author":"Agarwal","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2007.04.009_bib35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/ard.2003.015933","article-title":"Infliximab treatment for rheumatoid arthritis, with dose titration based on the disease activity score: dose adjustments are common but not always sufficient to assure sustained benefit","volume":"63","author":"Sidiropoulos","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2007.04.009_bib36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/ard.61.9.793","article-title":"Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden","volume":"61","author":"Geborek","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2007.04.009_bib37","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/ar2001","article-title":"Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity","volume":"8","author":"Vander Cruyssen","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2007.04.009_bib38","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/ard.2005.045062","article-title":"Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis","volume":"65","author":"Finckh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2007.04.009_bib39","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/ard.2004.030924","article-title":"Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial","volume":"64","author":"Fransen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2007.04.009_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X0700231X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X0700231X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:43:54Z","timestamp":1737359034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X0700231X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S1297319X0700231X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2007.04.009","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}